Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Other(3)

Detailed Status

unknown3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

unknown3100%

Recent Activity

0 active trials
Showing 3 of 3
unknownphase_2

Stem Cells Treatment for Extremely Complex Fistulae (HULPCIR)

NCT01586715
unknownphase_1

Stromal Vascular Fraction (SVF) for Treatment of Enterocutaneous Fistula (HULPUTC)

NCT01584713
unknownphase_1

Stromal Vascular Fraction (SVF) for Treatment of Recto-vaginal Fistula

NCT01548092

Clinical Trials (3)

Showing 3 of 3 trials
NCT01586715Phase 2

Stem Cells Treatment for Extremely Complex Fistulae (HULPCIR)

Unknown
NCT01584713Phase 1

Stromal Vascular Fraction (SVF) for Treatment of Enterocutaneous Fistula (HULPUTC)

Unknown
NCT01548092Phase 1

Stromal Vascular Fraction (SVF) for Treatment of Recto-vaginal Fistula

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3